低剂量西罗莫司治疗新生儿和婴儿卡波西样血管内皮瘤的成功管理
Successful Management of Neonatal and Infantile Kaposiform Hemangioendothelioma with Low-Dose Sirolimus Therapy.
作者信息
Uematsu Yoshimasa, Konishi Ken-Ichiro, Tanaka Kiyoshi, Takayasu Hajime, Watanabe Eiichiro, Tomari Takuji, Isohata Hitoshi, Nakanishi Hidehiko, Ochiai Daigo, Kumamoto Yusuke
机构信息
Department of General-Pediatric Hepatobiliary Pancreatic Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.
Division of Pediatric Surgery, Research and Development Center for New Medical Frontiers, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.
出版信息
J Pediatr Clin Pract. 2025 Jul 7;17:200161. doi: 10.1016/j.jpedcp.2025.200161. eCollection 2025 Sep.
Sirolimus is reportedly effective for kaposiform hemangioendothelioma. However, data on the efficacy of low-dose sirolimus therapy remain limited. This report presents two cases of neonatal and infantile kaposiform hemangioendothelioma associated with Kasabach-Merritt phenomenon successfully treated with low-dose sirolimus (serum level: 2-6 ng/mL) without any adverse events.
据报道，西罗莫司对卡波西样血管内皮瘤有效。然而，关于低剂量西罗莫司治疗疗效的数据仍然有限。本报告介绍了两例与卡萨巴赫-梅里特现象相关的新生儿和婴儿卡波西样血管内皮瘤，用低剂量西罗莫司（血清水平：2 - 6 ng/mL）成功治疗，且无任何不良事件。
Zotero 插件